|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Preparation, charac- terizatlon, cytotoxicity and transfection efficiency of poly(DL-lactide-co- glycolide) and poly(DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA 显示文摘 | Basarkar A Devineni D Palaniappan R Singh J | 2007 | Int J Pharm2007，343，12： | 1 |
| 2 | Pharmcolcinetics of nateglinide in renally impaired diabertic patients显示文摘 | Devineni D Walter Y H Smith H T | 2003 | J Clin Pharmacol2003，43，2： | 1 |
| 3 | Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors显示文摘 | DEVINENI D KLENI-SZANTO A | 1995 | J Neurooncol1995，24，1： | 1 |
| 4 | Canagliflozin, a novel inhibitor ofsodium glucose co-transporter 2,dose dependently reduces calculatedrenal threshold for glucose excretion and increases urinary glucoseexcretion in healthy subjects 显示文摘 | Sha S Devineni D Ghosh A | 2011 | Diabetes Obesity & Metabolism2011，13，7： | 1 |
| 5 | In vivo microdialysis to characterize drug transport in brain tumors:analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats显示文摘 | DEVINENI D KLEIN-SZANTO A GAHO J M | 1996 | Cancer Chemother Pharmacol1996，38，6： | 1 |
| 6 | Pharmacokinetics of nateglinide in renally impaired diabetic patients显示文摘 | Devineni D Walter Y H Smith H T | 2003 | J Clin Pharmacol2003，43，2： | 1 |
| 7 | Preparation and in vitro evaluation of magnetic microsphere-methotrexate conjugate drug delivery systems 显示文摘 | Devineni D Blanton CD Gallo JM | 2005 | Bioconjug Chem2005，6，2： | 1 |
| 8 | Pharmacokinetics of nateglinide in renally impaired diabetic patients显示文摘 | Devineni D Walter YH Smith HT | 2003 | J Clin Pharmacol2003，43，2： | 1 |
| 9 | Pharmacokinetics of nateglinide in renally impaired diabetic patients 显示文摘 | Devineni D Walter YH Smith HT | 2003 | J Clin Pharmacol2003，43，2： | 1 |
| 10 | Inhibition of expression of antiapoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line(PC-3)by methyl jasmonate显示文摘 | Ezekwudo D Shashidharamurthy R Devineni D | 2008 | Cancer Lett2008，270，2： | 1 |
| 11 | Pharmacok inetics of nateglinide in renally im paired diabetic patients显示文摘 | Devineni D Walter Y H Smith H T er al | 2003 | J Clin Pharmacol2003，43，2： | 1 |
| 12 | In vivo microdialysis to characterize drug transport brain tumors:analysis of methotrexate uptake in rat glioma-2(RG-2)-beafing rats显示文摘 | Devineni D Klein-Szanto A Galld JM | 1996 | Cancer Chemother Pharmacol1996，38，6： | 1 |
| 13 | Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose ex- cretion in healthy subjects 显示文摘 | Sha S Devineni D Gosh A | 2011 | Diabetes Obes Metab2011，13，7： | 1 |
| 14 | Pharmacokinetics and pharmacodynamies of eanagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjeets with type 2 diabetes mellitus 显示文摘 | Devineni D Curtin CR Polidori D | 2013 | J Clin Phar- macol2013，53，6： | 1 |
| 15 | Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not op- timally controlled on insulin 显示文摘 | Devineni D Morrow L Hompesch M | 2012 | Diabetes Obes Metab2012，14，6： | 1 |
| 16 | Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin 显示文摘 | DEVINENI D MORROW L HOMPESCH M | 2012 | Diabetes Obes Metab2012，14，6： | 1 |
| 17 | Canagliflozin, a novelinhibitor of sodium glucose co-transporter 2,induces dosedepen-dent urinary glucose excretion in healthy subjects 显示文摘 | SHA S DEVINENI D GOSH A | 2010 | DiabetesObes Metab2010，59，11： | 1 |
| 18 | Pharmacoki-netics and pharmacodynamics of canagliflozin,a sodium glucoseco-transporter 2 inhibitor, in subjects with type 2 diabetes melli-tus 显示文摘 | DEVINENI D CURTIN CR POLIDORI D | 2013 | J Clin Pharmacol2013，53，6： | 1 |
| 19 | Canaglifloz-in improves glycaemic control over 28 days in subjects with type 2diabetes not optimally controlled on insulin 显示文摘 | DEVINENI D MORROW L HOMPESCH M | 2012 | Diabetes ObesMetab2012，14，6： | 1 |
| 20 | Canagliflozin,a novel inhibitor of sodium glucose co-transporter 2,dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects显示文摘 | Sha S Devineni D Ghosh A | 2011 | Diabetes Obes Metab2011，13，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员